Abstract:Enterovirus 71 (EV71) has emerged as a neurological virus causing life-threatening diseases in young children and infants. Although EV71 vaccines in development have presented promising results in several clinical trials, the identified key antigen for improving the broad protective efficacy of EV71 vaccines has not been well investigated. In this report, we show that different multiplicities of infection (MOIs) of the B4(E59) virus significantly affect EV71 vaccine production in a serum-free microcarrier bioreactor system. The antigens produced from high MOIs of 10-1 and 10-2 exhibited higher yield and more infectious full particle (FP) contents in the EV71 vaccines than those produced with low MOIs of 10-4 and 10-6, leading to better cross-neutralizing efficacy. The C4(E36) neutralization results showed that only antisera raised from EV71 FPs provided substantial neutralizing titers against C4(E36), whereas empty particles (EPs) of EV71 conferred no efficacy. Competitive ELISA showed that anti-FP mainly binds to FPs and that 20% of antibodies bind to EPs, whereas most anti-EP binds EPs, with only 10% antibodies binding to FPs. VP1-adsorbed anti-FP lost most of the virus neutralization efficiency, suggesting that the VP1 subunit of FP is the major immunogenic antigen determining the ability of the EV71 vaccine to elicit cross-neutralizing antibodies against EV71 virus subtypes. These findings demonstrate that the high-MOI production approach is significantly correlated with FP productivity, thereby improving the cross-neutralization efficacy of an EV71 vaccine and providing the basis for a better vaccine design against widespread EV71 viruses.

Preparation and characterization of enterovirus 71 VP1 monoclonal antibody

[Preparation of monoclonal antibody against enterovirus 71 capsid protein VP1].

Expression of VP0 Protein of Enterovirus 71 and Generation of Its Polyclonal Antibodies

Prokaryotic expression and preliminary characterization of recombinant enterovirus71 VP1 protein

Preparation of monoclonal antibodies against 3D protein of EV71 based on HBc particles as expression vector

Structural and functional analysis of a potent human neutralizing antibody against enterovirus A71

Generation and Characterization of a Protective Mouse Monoclonal Antibody Against Human Enterovirus 71

Preparation and Identification of Monoclonal Antibodies Against VP1 Protein of Porcine Encephalomyocarditis Virus

Identification of specific antigenic epitope at N-terminal segment of enterovirus 71 (EV-71) VP1 protein and characterization of its use in recombinant form for early diagnosis of EV-71 infection

In Vivo Time-Related Evaluation of a Therapeutic Neutralization Monoclonal Antibody Against Lethal Enterovirus 71 Infection in a Mouse Model.

Characterization of the Antibody Response Against EV71 Capsid Proteins in Chinese Individuals by NEIBM-ELISA.

Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop.

The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus

Enterovirus 71 viral capsid protein linear epitopes: Identification and characterization

Development and Characterization of Monoclonal Antibodies Against VP1 Protein of O Type Foot-and-mouth Disease Virus

Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses

Antigenic characteristics of the complete and truncated capsid protein VP1 of enterovirus 71

Preparation and characterization of two monoclonal antibodies against pseudorabies virus

Development of a Specific Latex Agglutination Test to Detect Antibodies of Enterovirus 71

Expression and purification of enterovirus type 71 polyprotein P1 using Pichia pastoris system

Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71